|
ADVANCE
 |
Author(s) |
Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, Soukhomovskaia O, Ferrari R |
 |
Title(s) |
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty |
|
Reference(s) |
J Am Coll Cardiol 2004;44:14–9 |
|
Disease |
Acute coronary syndromes |
|
Purpose |
To evaluate the safety and efficacy of high-dose bolus tirofiban in high-risk patients undergoing percutaneous coronary intervention |
|
Study design |
Randomised, double-blind, placebo-controlled |
|
Follow-up |
Median 185 days |
|
Patients |
202 patients (101 tirofiban, 101 placebo), mean age 69 years, undergoing elective or urgent percutaneous coronary intervention with clinical or angiographic high-risk features |
|
Treatment regimen |
Tirofiban, 25 µg/kg iv bolus, then 0.15 µg/kg/min sc for 24–48 h, or placebo |
|
Concomitant therapy |
ASA, thienopyridine, unfractionated heparin |
|
Results |
The composite primary endpoint of death, nonfatal MI, urgent target vessel revascularisation or thrombotic bailout GP IIb/IIIa inhibitor treatment was reached by 20% of patients in the tirofiban group and 35% of those in the placebo group (hazard ratio 0.51, 95% CI 0.29–0.88; p = 0.01). The safety profile did not differ between the two groups |
|
|
|
